Evaluation of the Reimbursement Status and Market Access of Oncology Medicines in Türkiye: A Descriptive Analysis

OBJECTIVES: The swift advancements in the pharmaceutical industry have resulted in a wide array of medical treatments, particularly in the field of oncology. However, access to these medicines varies according to the health policies of countries. The aim of this study is to evaluate the oncology medicines market in Türkiye in terms of reimbursement status.

METHODS: In the study, the reimbursement status, original-generic distribution, and market access agreements of oncology medicines in the Turkish market were examined. The necessary data for the study were obtained from relevant lists published by the Social Security Institution and the Turkish Medicines and Medical Devices Agency. Data has been transferred to Windows Office Excel and conducted descriptive analysis.

RESULTS: According to the analysis results, there are 338 products in the Turkish oncology drug market, and a significant portion of these drugs are covered by reimbursement (283/338). Of the 283 reimbursed drugs, 155 are classified as generic products and 128 as original products. Among the reimbursed drugs, 23 have been included in the reimbursement scheme through market access agreements, which are specifically applied for the treatment of particularly costly diseases in Türkiye. The remaining 260 drugs are covered under standard reimbursement agreements. All 23 products reimbursed through market access agreements are original products, while the remaining 105 original products are included under standard reimbursement methods.

CONCLUSIONS: In conclusion, the Turkish oncology drug market demonstrates a strong commitment to ensuring access to a wide range of cancer treatments, with the majority of available products being covered by reimbursement schemes. Furthermore, the use of market access agreements for particularly costly diseases underscores the importance of innovative pricing and reimbursement strategies to enhance the availability of essential, high-cost original drugs. This comprehensive approach to reimbursement facilitates improved treatment outcomes and accessibility for cancer patients across Türkiye.